Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 3
1995 7
1996 10
1997 11
1998 22
1999 9
2000 15
2001 12
2002 12
2003 6
2004 15
2005 15
2006 6
2007 12
2008 10
2009 15
2010 13
2011 9
2012 9
2013 6
2014 8
2015 7
2016 7
2017 5
2018 6
2019 6
2020 6
2021 4
2022 3
2023 2
2024 2
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Results by year

Filters applied: . Clear all
Page 1
Ipamorelin, the first selective growth hormone secretagogue.
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Raun K, et al. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. Eur J Endocrinol. 1998. PMID: 9849822
Again, this was very similar to GHRP-6 (ED50 = 3.9+/-1.4 nmol/kg and Emax = 74+/-7ng GH/ml plasma). GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma). ...None of the GH secretagogues tested affected FSH, LH, PR …
Again, this was very similar to GHRP-6 (ED50 = 3.9+/-1.4 nmol/kg and Emax = 74+/-7ng GH/ml plasma). GHRP-2 displayed higher po …
Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN.
[No authors listed] [No authors listed] Drugs R D. 2004;5(4):236-9. doi: 10.2165/00126839-200405040-00011. Drugs R D. 2004. PMID: 15230633 Review.
Pralmorelin [GPA 748, GHRP 2, growth hormone-releasing peptide 2, KP-102 D, KP 102 LN] is an orally active, synthetic growth hormone-releasing peptide from a series of compounds that were developed by Polygen in Germany and Tulane …
Pralmorelin [GPA 748, GHRP 2, growth hormone-releasing peptide 2, KP-102 D, KP 102 LN] is a …
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.
Laferrère B, Abraham C, Russell CD, Bowers CY. Laferrère B, et al. J Clin Endocrinol Metab. 2005 Feb;90(2):611-4. doi: 10.1210/jc.2004-1719. J Clin Endocrinol Metab. 2005. PMID: 15699539 Free PMC article.
GHRP-2 is a synthetic agonist of ghrelin, the newly-discovered gut peptide which binds to the growth hormone (GH) secretagogue receptor. ...These data are the first to demonstrate that GHRP-2, like ghrelin, increases food intake, suggesting that GHR …
GHRP-2 is a synthetic agonist of ghrelin, the newly-discovered gut peptide which binds to the growth hormone (GH) secretagogue …
GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1.
Yamamoto D, Ikeshita N, Matsubara T, Tasaki H, Herningtyas EH, Toda K, Iida K, Takahashi Y, Kaji H, Chihara K, Okimura Y. Yamamoto D, et al. Life Sci. 2008 Feb 27;82(9-10):460-6. doi: 10.1016/j.lfs.2007.11.019. Epub 2007 Dec 5. Life Sci. 2008. PMID: 18191156
Recent reports suggest that Atrogin-1 and MuRF1, E3 ubiquitin ligases, play a pivotal role in muscle atrophy. In the present study, effect of Growth Hormone Releasing Peptide-2 (GHRP-2), a GH secretagogue receptor (GHS-R) agonist, …
Recent reports suggest that Atrogin-1 and MuRF1, E3 ubiquitin ligases, play a pivotal role in muscle atrophy. In the present study, effect o …
Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.
Chen C, Farnworth P, Petersenn S, Musgrave I, Canny BJ, Clarke IJ. Chen C, et al. Endocrine. 1998 Aug;9(1):71-7. doi: 10.1385/ENDO:9:1:71. Endocrine. 1998. PMID: 9798733
Effect of growth hormone-releasing peptide-2 (GHRP-2) on ovine somatotrophs is abolished by a growth hormone-releasing factor (GRF) receptor antagonist, which raises the possibility that GHRP-2 may act on GRF receptor …
Effect of growth hormone-releasing peptide-2 (GHRP-2) on ovine somatotrophs is abolished by …
Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.
Semenistaya E, Zvereva I, Thomas A, Thevis M, Krotov G, Rodchenkov G. Semenistaya E, et al. Drug Test Anal. 2015 Oct;7(10):919-25. doi: 10.1002/dta.1787. Epub 2015 Apr 13. Drug Test Anal. 2015. PMID: 25869809
To develop an effective method for GHRPs anti-doping control we have investigated metabolites of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin in urine after nasal administration. Each compound was administrated to one volunteer. ...GHRP-1 (2-4) free acid …
To develop an effective method for GHRPs anti-doping control we have investigated metabolites of GHRP-1, GHRP-2, GHRP-6 …
GHRP-2, GHRH and SRIF interrelationships during chronic administration of GHRP-2 to humans.
Bowers CY, Granda-Ayala R. Bowers CY, et al. J Pediatr Endocrinol Metab. 1996 Jun;9 Suppl 3:261-70. J Pediatr Endocrinol Metab. 1996. PMID: 8887169 Clinical Trial.
Studies with chronic GHRP-2 or GHRH administration were performed to demonstrate and better understand the interrelationships between GHRP-2, GHRH and SRIF. Normal younger and older men and women received chronic GHRP-2, GHRH or GHRP …
Studies with chronic GHRP-2 or GHRH administration were performed to demonstrate and better understand the interrelationships …
The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison.
Kinoshita Y, Tominaga A, Usui S, Arita K, Sakoguchi T, Sugiyama K, Kurisu K. Kinoshita Y, et al. Endocr J. 2013;60(1):97-105. doi: 10.1507/endocrj.ej12-0230. Epub 2012 Oct 19. Endocr J. 2013. PMID: 23079545 Free article.
However, the glucagon, arginine, and GH releasing peptide-2 (GHRP-2) test are recommended as alternatives in Japan. The objective of this study was to evaluate the arginine and GHRP-2 tests as alternatives to the ITT for the diagnosis of AGHD in …
However, the glucagon, arginine, and GH releasing peptide-2 (GHRP-2) test are recommended as alternatives in Japan. The …
Is GHRH receptor essential to GHRP-2-induced GH secretion in primary cultured rat pituitary cells?
Roh SG, Chen C, Choi KC, Shrestha Y, Sasaki S. Roh SG, et al. Endocrinology. 2002 May;143(5):1964-7. doi: 10.1210/endo.143.5.8893. Endocrinology. 2002. PMID: 11956179
Treatment with antisense GHS-R ON reduced (but not abolished) GHRP-2-induced GH secretion although GHRH-induced GH secretion was not altered. GHRH-stimulated GH secretion was totally abolished by the treatment with antisense GHRH-R ON, whereas GHRP-2 i …
Treatment with antisense GHS-R ON reduced (but not abolished) GHRP-2-induced GH secretion although GHRH-induced GH secretion w …
250 results